pegaspargase + etoposide + gemcitabine

Pegaspargase + etoposide + gemcitabine (PEG) is a combination chemotherapy regimen primarily investigated by Sun Yat-sen University for the treatment of extranodal natural killer/T-cell lymphoma (ENKTL). The regimen utilizes pegaspargase, a pegylated L-asparaginase that depletes serum asparagine, an amino acid essential for the survival of certain lymphoma cells. This is combined with etoposide, which targets DNA topoisomerase II to induce double-stranded DNA breaks, and gemcitabine, a nucleoside analog that inhibits DNA synthesis by targeting ribonucleoside-diphosphate reductase and DNA polymerase. The PEG regimen is typically evaluated as a first-line or salvage therapy for patients with aggressive, often refractory, NK/T-cell malignancies.

Other names

PEG-ASP + etoposide + gemcitabinePEG chemotherapyPEG regimen